Ventrus Biosciences Inc. (VTUS)

[PJO]

Quote copied from says have enought cash for a while ??????????

Based on our cash position at December 31, 2013, the receipt of approximately $1.8 million in net proceeds in January 2014 from our at-the-market program, and our analysis of our future development costs, we believe that our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through the initial launch and commercialization of VEN 307 and into the second quarter of 2016. We have based these estimates on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, which would cause us to require additional capital earlier.